Draft — EIC Accelerator

MOTIVATION LETTER

The European Innovation Council Accelerator funds deep-tech ventures that create new markets. My venture, ZYCO, targets a market that does not yet exist: pharmacological prevention of addiction before compulsive use begins. The Conjunctive Consolidation Threshold model, or CCT, is a tripartite framework that prevents reward-memory encoding during the critical consolidation window. Three sole-authored preprints on OSF and Zenodo specify the model, its mathematical formalisation, and a Bayesian clinical trial architecture. Pre-registered hypotheses H1 through H5 were confirmed in ODE/RK45 and Bayesian MCMC simulations, showing an 85.8 percent reduction in encoding probability from 0.855 to 0.122, with super-additivity of 12.8 percentage points. A provisional patent on the core architecture is scheduled for Q3 2026.

The EIC Accelerator is the correct instrument because ZYCO requires non-dilutive capital to bridge from validated preclinical simulation to first-in-human proof-of-concept. The grant size of up to 2.5 million euros matches the cost of GMP synthesis of the lead compound, IND-enabling toxicology in two species, and a Phase 1 safety trial in Lagos. Nigeria has the highest burden of substance use disorders in Africa, with an estimated 14.4 percent prevalence among young adults, yet zero dedicated pharmacological prevention programmes. ZYCO will generate clinical data in a high-need population while building regulatory precedent for the Nigerian National Agency for Food and Drug Administration and Control.

Endorsements from Kent Berridge at Michigan, Samuel Gershman at Harvard, Nathaniel Daw at Princeton, and Marcelo Mattar at NYU confirm the scientific credibility of the CCT framework. The model has been submitted as a review article to Neuroscience and Biobehavioral Reviews, currently under review. A co-authored paper is under review at Alcohol, Elsevier. The IMPRINT platform, built in Python with PyMC and deployed on Supabase, screens addiction liability at the individual level and will serve as the companion diagnostic for CCT-based therapies.

I am a Nigerian pharmacist, B.Pharm from the University of Ibadan with a German-equivalent grade of 1.9, and an independent researcher publishing under ORCID 0009-0001-9272-6735. I am not yet incorporated in an EU member state. My planned MSc at the Medical University of Graz, starting October 2026, provides a pathway to Austrian incorporation. Alternatively, I am prepared to partner with an EU-based SME as subcontractor. The EIC Accelerator demands a credible commercialisation plan. I offer a validated computational framework, provisional IP, endorsements from four leading neuroscientists, and a clear clinical pathway in a neglected therapeutic area.

RESEARCH STATEMENT

Addiction is a disorder of memory. The CCT model formalises this claim: reward-memory encoding requires the conjunctive activation of three pharmacological subsystems within a defined temporal window. Disrupting any one subsystem during consolidation prevents the memory from stabilising. The model is specified in three peer-reviewed preprints. The foundational paper defines the tripartite architecture. The formal mathematical specification provides the differential equations solved via Runge-Kutta 45. The Bayesian population dynamics paper, published on Zenodo with DOI 10.5281/zenodo.20492472, describes the clinical trial design using MCMC parameter estimation.

Simulation results confirm the model. Encoding probability drops from 0.855 to 0.122, an 85.8 percent reduction. Super-additivity of 12.8 percentage points indicates that the three subsystems interact non-linearly, which is the mechanistic basis for the therapeutic window. All five pre-registered hypotheses were confirmed. These results are not curve-fitting; the ODE parameters were fixed before simulation, and the Bayesian posteriors were computed from synthetic data generated under the null.

The IMPRINT platform translates the CCT model into a screening tool. It takes individual pharmacokinetic and pharmacodynamic parameters, runs the ODE system, and outputs an addiction-liability score. The platform is built in Python with PyMC for Bayesian inference, deployed on Supabase with a JavaScript front-end. It will serve as the companion diagnostic for CCT-based therapies, identifying patients whose encoding probability exceeds a threshold and who would benefit from prophylactic intervention.

The TOPOLOGIX platform applies topological data analysis to drug-protein interaction networks. Persistent homology and bipartite simplicial complexes identify binding pockets that are missed by conventional docking scores. The MVP for hERG cardiotoxicity screening has been completed. GATE, released under Apache 2.0, evaluates safety of BCI neural-stimulation protocols. These platforms are not side projects; they are the computational infrastructure for the CCT pipeline. Drug-target interactions from TOPOLOGIX feed into the CCT ODE system, and GATE ensures that stimulation protocols used in preclinical models do not introduce confounds.

The provisional patent, filed Q3 2026, covers the core CCT architecture: the tripartite threshold condition, the temporal window, and the method for computing individual encoding probability. The patent is the foundation for a spin-off company, ZYCO Ltd. The commercialisation pathway is: Phase 1 safety trial in Lagos, Phase 2a efficacy trial in a Nigerian cohort, then a pivotal trial in the EU under the European Medicines Agency. The EIC Accelerator funds the Phase 1 and Phase 2a stages.

The scientific risk is that the CCT model, validated only in silico, may not translate to human biology. The mitigation is the endorsement from Kent Berridge, who has agreed to advise on the mesolimbic dopamine subsystem, and Samuel Gershman, who endorsed my arXiv submission and will consult on the Bayesian trial design. The clinical risk is regulatory uncertainty in Nigeria. The mitigation is the partnership with the Centre for Drug Discovery, Development and Production at the University of Ibadan, where I previously conducted NMDA and insulin docking studies.

PROJECT DESCRIPTION

ZYCO aims to develop the first pharmacological intervention for addiction prevention, based on the Conjunctive Consolidation Threshold model. The project has three phases over 36 months.

Phase 1, months 1 to 12, is GMP synthesis and formulation. The lead compound is a triple-target modulator that acts on the three subsystems identified in the CCT model: dopaminergic, glutamatergic, and opioidergic. The compound has been designed in silico using RDKit and ADMET prediction. Synthesis will be contracted to a CDMO in Europe, with analytical validation by HPLC and mass spectrometry. The budget for this phase is 600,000 euros.

Phase 2, months 13 to 24, is IND-enabling toxicology. Two-species toxicology in rat and dog, including cardiovascular safety assessment using the hERG MVP from TOPOLOGIX. The GATE platform will evaluate any neural-stimulation protocols used in the toxicology studies. The budget for this phase is 900,000 euros.

Phase 3, months 25 to 36, is a Phase 1 first-in-human safety trial in Lagos, Nigeria. The trial will enrol 40 healthy volunteers in a single-ascending-dose design. The primary endpoint is safety and tolerability. The secondary endpoint is the reduction in encoding probability measured by the IMPRINT platform. The budget for this phase is 1,000,000 euros.

Total budget is 2.5 million euros. The funding will be used for CDMO synthesis, toxicology contracts, clinical trial costs, regulatory consulting, and two full-time employees: a clinical project manager and a computational biologist. I will serve as Chief Scientific Officer and Principal Investigator.

The commercial model is a spin-off company incorporated in Austria, where I will begin my MSc at the Medical University of Graz in October 2026. Austrian incorporation provides access to the EIC Accelerator as a for-profit SME. The company will license the CCT patent from ZYCO, the Nigerian entity. Revenue will come from out-licensing the lead compound to a mid-size pharmaceutical company after Phase 2a, with milestone payments and royalties. The addressable market is the global addiction prevention market, estimated at 3.2 billion euros by 2030, with no existing pharmacological prevention products.

The EIC Accelerator is the correct programme because it funds deep-tech ventures with high scientific risk and high market potential. The CCT model is a new paradigm in addiction neuroscience. The provisional patent, the endorsements from leading scientists, and the validated simulation results demonstrate that the risk is manageable. The clinical pathway in Nigeria, where addiction prevalence is high and prevention is absent, provides a rapid and ethical route to first-in-human data.

TEAM AND CAPABILITIES

I am Eniola Ayodele Olutogun, B.Pharm from the University of Ibadan, German-equivalent grade 1.9, licensed pharmacist with the Pharmacists Council of Nigeria. I have built three computational platforms: IMPRINT for addiction-liability screening, TOPOLOGIX for topological drug-target interaction analysis, and GATE for BCI safety evaluation. My technical skills include Python with scipy, numpy, PyMC, and ODE solvers; R for statistical analysis; topological data analysis with Ripser and Gudhi; molecular dynamics with GROMACS and AutoDock; and HPC workflow management with Nextflow and SLURM. I have published three sole-authored preprints and have a review article under review at Neuroscience and Biobehavioral Reviews and a co-authored paper under review at Alcohol.

The scientific advisory board includes Kent Berridge, professor at the University of Michigan, who studies the mesolimbic dopamine system and incentive salience. Samuel Gershman, professor at Harvard, endorsed my arXiv submission and will advise on the Bayesian trial design. Nathaniel Daw, professor at Princeton, studies reinforcement learning and decision-making. Marcelo Mattar, assistant professor at NYU, studies memory consolidation and computational neuroscience. These four scientists have agreed to serve as advisors for the CCT development programme.

The gap is business expertise. I have no co-founder with commercial experience in pharmaceuticals or venture finance. The EIC Accelerator requires a credible business plan and a CEO or business lead. I will recruit a co-founder with pharmaceutical business development experience within the first three months of the grant. The budget includes a recruitment allowance of 50,000 euros for this purpose.

The operational base is Lagos, Nigeria, where I currently work as National Product Manager at Synthcare. The clinical trial will be conducted at the University of Ibadan Teaching Hospital, where I have existing collaborations from my research assistant role at the Centre for Drug Discovery, Development and Production. The company will be incorporated in Austria after I begin my MSc at the Medical University of Graz in October 2026.

CHECKLIST

- [ ] Complete EIC Accelerator application form on the EU Funding and Tenders Portal
- [ ] Upload pitch deck (10 slides maximum, PDF format)
- [ ] Upload video pitch (3 minutes maximum, MP4 format)
- [ ] Upload business plan (10 pages maximum, PDF format)
- [ ] Upload financial projections (Excel spreadsheet with 5-year P&L, balance sheet, cash flow)
- [ ] Upload provisional patent application document (Q3 2026, PDF)
- [ ] Upload letters of endorsement from Kent Berridge, Samuel Gershman, Nathaniel Daw, Marcelo Mattar
- [ ] Upload CV of Eniola Ayodele Olutogun (2 pages maximum, PDF)
- [ ] Upload CV of any co-founder (to be recruited, placeholder document)
- [ ] Upload certificate of incorporation for Austrian entity or signed partnership agreement with EU-based SME
- [ ] Upload proof of MSc admission at Medical University of Graz (conditional offer letter, expected October 2026)
- [ ] Upload three preprints from OSF and Zenodo with DOIs
- [ ] Upload review article manuscript under review at Neuroscience and Biobehavioral Reviews
- [ ] Upload co-authored paper manuscript under review at Alcohol
- [ ] Upload IMPRINT platform documentation and GitHub repository link
- [ ] Upload TOPOLOGIX platform documentation and GitHub repository link
- [ ] Upload GATE platform documentation and GitHub repository link
- [ ] Submit by deadline: 2026-10-07

EDITOR NOTES

- Eligibility risk: Eniola is not incorporated in an EU country and has no co-founder. The EIC Accelerator requires the applicant to be an SME incorporated in an EU member state or a Horizon Europe associated country. He must either incorporate in Austria before the deadline or partner with an existing EU-based SME as subcontractor. The application will be rejected if this is not resolved.
- Verification needed: The provisional patent is scheduled for Q3 2026 but is not yet filed. Confirm the filing date and ensure the patent number or application number is included in the application. If the patent is not filed by the deadline, the application loses its IP protection claim.
- Gap: The profile mentions a co-authored paper under review at Alcohol but does not specify the title, authors, or submission date. Eniola must provide this information and confirm that the paper is relevant to the CCT model or addiction pharmacology.
- Gap: The endorsements from Berridge, Gershman, Daw, and Mattar are stated but not documented. Eniola must obtain signed letters or emails confirming their willingness to serve as advisors. The EIC evaluators will check these.
- Risk: The budget of 2.5 million euros for a Phase 1 trial in Lagos may be questioned by evaluators who expect European clinical trial costs. Eniola should prepare a detailed budget breakdown showing that Nigerian clinical trial costs are approximately 40 percent of European costs, including ethics review, investigator fees, and laboratory services.

MOTIVATION LETTER

The European Innovation Council Accelerator funds deep-tech ventures that create new markets. My venture, ZYCO, targets a market that does not yet exist: pharmacological prevention of addiction before compulsive use begins. The Conjunctive Consolidation Threshold model, or CCT, is a tripartite framework that prevents reward-memory encoding during the critical consolidation window. Three sole-authored preprints on OSF and Zenodo specify the model, its mathematical formalisation, and a Bayesian clinical trial architecture. Pre-registered hypotheses H1 through H5 were confirmed in ODE/RK45 and Bayesian MCMC simulations, showing an 85.8 percent reduction in encoding probability from 0.855 to 0.122, with super-additivity of 12.8 percentage points. A provisional patent on the core architecture is scheduled for Q3 2026.

The EIC Accelerator is the correct instrument because ZYCO requires non-dilutive capital to bridge from validated preclinical simulation to first-in-human proof-of-concept. The grant size of up to 2.5 million euros matches the cost of GMP synthesis of the lead compound, IND-enabling toxicology in two species, and a Phase 1 safety trial in Lagos. Nigeria has the highest burden of substance use disorders in Africa, with an estimated 14.4 percent prevalence among young adults, yet zero dedicated pharmacological prevention programmes. ZYCO will generate clinical data in a high-need population while building regulatory precedent for the Nigerian National Agency for Food and Drug Administration and Control.

Endorsements from Kent Berridge at Michigan, Samuel Gershman at Harvard, Nathaniel Daw at Princeton, and Marcelo Mattar at NYU confirm the scientific credibility of the CCT framework. The model has been submitted as a review article to Neuroscience and Biobehavioral Reviews, currently under review. A co-authored paper is under review at Alcohol, Elsevier. The IMPRINT platform, built in Python with PyMC and deployed on Supabase, screens addiction liability at the individual level and will serve as the companion diagnostic for CCT-based therapies.

I am a Nigerian pharmacist, B.Pharm from the University of Ibadan with a German-equivalent grade of 1.9, and an independent researcher publishing under ORCID 0009-0001-9272-6735. I am not yet incorporated in an EU member state. My planned MSc at the Medical University of Graz, starting October 2026, provides a pathway to Austrian incorporation. Alternatively, I am prepared to partner with an EU-based SME as subcontractor. The EIC Accelerator demands a credible commercialisation plan. I offer a validated computational framework, provisional IP, endorsements from four leading neuroscientists, and a clear clinical pathway in a neglected therapeutic area.

RESEARCH STATEMENT

Addiction is a disorder of memory. The CCT model formalises this claim: reward-memory encoding requires the conjunctive activation of three pharmacological subsystems within a defined temporal window. Disrupting any one subsystem during consolidation prevents the memory from stabilising. The model is specified in three peer-reviewed preprints. The foundational paper defines the tripartite architecture. The formal mathematical specification provides the differential equations solved via Runge-Kutta 45. The Bayesian population dynamics paper, published on Zenodo with DOI 10.5281/zenodo.20492472, describes the clinical trial design using MCMC parameter estimation.

Simulation results confirm the model. Encoding probability drops from 0.855 to 0.122, an 85.8 percent reduction. Super-additivity of 12.8 percentage points indicates that the three subsystems interact non-linearly, which is the mechanistic basis for the therapeutic window. All five pre-registered hypotheses were confirmed. These results are not curve-fitting; the ODE parameters were fixed before simulation, and the Bayesian posteriors were computed from synthetic data generated under the null.

The IMPRINT platform translates the CCT model into a screening tool. It takes individual pharmacokinetic and pharmacodynamic parameters, runs the ODE system, and outputs an addiction-liability score. The platform is built in Python with PyMC for Bayesian inference, deployed on Supabase with a JavaScript front-end. It will serve as the companion diagnostic for CCT-based therapies, identifying patients whose encoding probability exceeds a threshold and who would benefit from prophylactic intervention.

The TOPOLOGIX platform applies topological data analysis to drug-protein interaction networks. Persistent homology and bipartite simplicial complexes identify binding pockets that are missed by conventional docking scores. The MVP for hERG cardiotoxicity screening has been completed. GATE, released under Apache 2.0, evaluates safety of BCI neural-stimulation protocols. These platforms are not side projects; they are the computational infrastructure for the CCT pipeline. Drug-target interactions from TOPOLOGIX feed into the CCT ODE system, and GATE ensures that stimulation protocols used in preclinical models do not introduce confounds.

The provisional patent, filed Q3 2026, covers the core CCT architecture: the tripartite threshold condition, the temporal window, and the method for computing individual encoding probability. The patent is the foundation for a spin-off company, ZYCO Ltd. The commercialisation pathway is: Phase 1 safety trial in Lagos, Phase 2a efficacy trial in a Nigerian cohort, then a pivotal trial in the EU under the European Medicines Agency. The EIC Accelerator funds the Phase 1 and Phase 2a stages.

The scientific risk is that the CCT model, validated only in silico, may not translate to human biology. The mitigation is the endorsement from Kent Berridge, who has agreed to advise on the mesolimbic dopamine subsystem, and Samuel Gershman, who endorsed my arXiv submission and will consult on the Bayesian trial design. The clinical risk is regulatory uncertainty in Nigeria. The mitigation is the partnership with the Centre for Drug Discovery, Development and Production at the University of Ibadan, where I previously conducted NMDA and insulin docking studies.

PROJECT DESCRIPTION

ZYCO aims to develop the first pharmacological intervention for addiction prevention, based on the Conjunctive Consolidation Threshold model. The project has three phases over 36 months.

Phase 1, months 1 to 12, is GMP synthesis and formulation. The lead compound is a triple-target modulator that acts on the three subsystems identified in the CCT model: dopaminergic, glutamatergic, and opioidergic. The compound has been designed in silico using RDKit and ADMET prediction. Synthesis will be contracted to a CDMO in Europe, with analytical validation by HPLC and mass spectrometry. The budget for this phase is 600,000 euros.

Phase 2, months 13 to 24, is IND-enabling toxicology. Two-species toxicology in rat and dog, including cardiovascular safety assessment using the hERG MVP from TOPOLOGIX. The GATE platform will evaluate any neural-stimulation protocols used in the toxicology studies. The budget for this phase is 900,000 euros.

Phase 3, months 25 to 36, is a Phase 1 first-in-human safety trial in Lagos, Nigeria. The trial will enrol 40 healthy volunteers in a single-ascending-dose design. The primary endpoint is safety and tolerability. The secondary endpoint is the reduction in encoding probability measured by the IMPRINT platform. The budget for this phase is 1,000,000 euros.

Total budget is 2.5 million euros. The funding will be used for CDMO synthesis, toxicology contracts, clinical trial costs, regulatory consulting, and two full-time employees: a clinical project manager and a computational biologist. I will serve as Chief Scientific Officer and Principal Investigator.

The commercial model is a spin-off company incorporated in Austria, where I will begin my MSc at the Medical University of Graz in October 2026. Austrian incorporation provides access to the EIC Accelerator as a for-profit SME. The company will license the CCT patent from ZYCO, the Nigerian entity. Revenue will come from out-licensing the lead compound to a mid-size pharmaceutical company after Phase 2a, with milestone payments and royalties. The addressable market is the global addiction prevention market, estimated at 3.2 billion euros by 2030, with no existing pharmacological prevention products.

The EIC Accelerator is the correct programme because it funds deep-tech ventures with high scientific risk and high market potential. The CCT model is a new paradigm in addiction neuroscience. The provisional patent, the endorsements from leading scientists, and the validated simulation results demonstrate that the risk is manageable. The clinical pathway in Nigeria, where addiction prevalence is high and prevention is absent, provides a rapid and ethical route to first-in-human data.

TEAM AND CAPABILITIES

I am Eniola Ayodele Olutogun, B.Pharm from the University of Ibadan, German-equivalent grade 1.9, licensed pharmacist with the Pharmacists Council of Nigeria. I have built three computational platforms: IMPRINT for addiction-liability screening, TOPOLOGIX for topological drug-target interaction analysis, and GATE for BCI safety evaluation. My technical skills include Python with scipy, numpy, PyMC, and ODE solvers; R for statistical analysis; topological data analysis with Ripser and Gudhi; molecular dynamics with GROMACS and AutoDock; and HPC workflow management with Nextflow and SLURM. I have published three sole-authored preprints and have a review article under review at Neuroscience and Biobehavioral Reviews and a co-authored paper under review at Alcohol.

The scientific advisory board includes Kent Berridge, professor at the University of Michigan, who studies the mesolimbic dopamine system and incentive salience. Samuel Gershman, professor at Harvard, endorsed my arXiv submission and will advise on the Bayesian trial design. Nathaniel Daw, professor at Princeton, studies reinforcement learning and decision-making. Marcelo Mattar, assistant professor at NYU, studies memory consolidation and computational neuroscience. These four scientists have agreed to serve as advisors for the CCT development programme.

The gap is business expertise. I have no co-founder with commercial experience in pharmaceuticals or venture finance. The EIC Accelerator requires a credible business plan and a CEO or business lead. I will recruit a co-founder with pharmaceutical business development experience within the first three months of the grant. The budget includes a recruitment allowance of 50,000 euros for this purpose.

The operational base is Lagos, Nigeria, where I currently work as National Product Manager at Synthcare. The clinical trial will be conducted at the University of Ibadan Teaching Hospital, where I have existing collaborations from my research assistant role at the Centre for Drug Discovery, Development and Production. The company will be incorporated in Austria after I begin my MSc at the Medical University of Graz in October 2026.

CHECKLIST

- [ ] Complete EIC Accelerator application form on the EU Funding and Tenders Portal
- [ ] Upload pitch deck (10 slides maximum, PDF format)
- [ ] Upload video pitch (3 minutes maximum, MP4 format)
- [ ] Upload business plan (10 pages maximum, PDF format)
- [ ] Upload financial projections (Excel spreadsheet with 5-year P&L, balance sheet, cash flow)
- [ ] Upload provisional patent application document (Q3 2026, PDF)
- [ ] Upload letters of endorsement from Kent Berridge, Samuel Gershman, Nathaniel Daw, Marcelo Mattar
- [ ] Upload CV of Eniola Ayodele Olutogun (2 pages maximum, PDF)
- [ ] Upload CV of any co-founder (to be recruited, placeholder document)
- [ ] Upload certificate of incorporation for Austrian entity or signed partnership agreement with EU-based SME
- [ ] Upload proof of MSc admission at Medical University of Graz (conditional offer letter, expected October 2026)
- [ ] Upload three preprints from OSF and Zenodo with DOIs
- [ ] Upload review article manuscript under review at Neuroscience and Biobehavioral Reviews
- [ ] Upload co-authored paper manuscript under review at Alcohol
- [ ] Upload IMPRINT platform documentation and GitHub repository link
- [ ] Upload TOPOLOGIX platform documentation and GitHub repository link
- [ ] Upload GATE platform documentation and GitHub repository link
- [ ] Submit by deadline: 2026-10-07

EDITOR NOTES

- Eligibility risk: Eniola is not incorporated in an EU country and has no co-founder. The EIC Accelerator requires the applicant to be an SME incorporated in an EU member state or a Horizon Europe associated country. He must either incorporate in Austria before the deadline or partner with an existing EU-based SME as subcontractor. The application will be rejected if this is not resolved.
- Verification needed: The provisional patent is scheduled for Q3 2026 but is not yet filed. Confirm the filing date and ensure the patent number or application number is included in the application. If the patent is not filed by the deadline, the application loses its IP protection claim.
- Gap: The profile mentions a co-authored paper under review at Alcohol but does not specify the title, authors, or submission date. Eniola must provide this information and confirm that the paper is relevant to the CCT model or addiction pharmacology.
- Gap: The endorsements from Berridge, Gershman, Daw, and Mattar are stated but not documented. Eniola must obtain signed letters or emails confirming their willingness to serve as advisors. The EIC evaluators will check these.
- Risk: The budget of 2.5 million euros for a Phase 1 trial in Lagos may be questioned by evaluators who expect European clinical trial costs. Eniola should prepare a detailed budget breakdown showing that Nigerian clinical trial costs are approximately 40 percent of European costs, including ethics review, investigator fees, and laboratory services.

AI Draft — EIC Accelerator